Eli Lilly, Pfizer stress independence of telehealth partners in response to senators

Nicole DeFeudis

Editor

In response to lawmakers’ concerns, Pfizer and Eli Lilly said last week that they do not influence telehealth partners and their clinicians to prescribe their …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Eli Lilly, Pfizer stress independence of telehealth partners in response to senators

Nicole DeFeudis

Editor

Sign up to read this article for free.

Lilly drops body mass ranges from FDA label for weight loss drug

GSK terminates Phase 2 trial of HBV therapeutic vaccine

Coherus makes final, $483M pivot away from biosimilars

Ipsen secures rights to preclinical T cell engager in $610M pact with French biotech

Janux soars on early prostate cancer data that could challenge Novartis' Pluvicto

Roche teams up with Chicago autoimmune biotech COUR Pharmaceuticals

Eli Lil­ly, Pfiz­er stress in­de­pen­dence of tele­health part­ners in re­sponse to sen­a­tors

Nicole DeFeudis

Editor

Sign up to read this article for free.

more like this

Lil­ly drops body mass ranges from FDA la­bel for weight loss drug

GSK ter­mi­nates Phase 2 tri­al of HBV ther­a­peu­tic vac­cine

Co­herus makes fi­nal, $483M piv­ot away from biosim­i­lars

Ipsen se­cures rights to pre­clin­i­cal T cell en­gager in $610M pact with French biotech

Janux soars on ear­ly prostate can­cer da­ta that could chal­lenge No­var­tis' Plu­vic­to

Roche teams up with Chica­go au­toim­mune biotech COUR Phar­ma­ceu­ti­cals

Eli Lilly, Pfizer stress independence of telehealth partners in response to senators

Lilly drops body mass ranges from FDA label for weight loss drug

GSK terminates Phase 2 trial of HBV therapeutic vaccine

Coherus makes final, $483M pivot away from biosimilars

Ipsen secures rights to preclinical T cell engager in $610M pact with French biotech

Janux soars on early prostate cancer data that could challenge Novartis' Pluvicto

Roche teams up with Chicago autoimmune biotech COUR Pharmaceuticals